Equillium Company Insiders

EQ Stock  USD 1.65  0.04  2.48%   
Equillium's insiders are aggressively selling. The analysis of the overall insider sentiment regarding Equillium suggests that virtually all insiders are panicking. Equillium employs about 44 people. The company is managed by 24 executives with a total tenure of roughly 143 years, averaging almost 5.0 years of service per executive, having 1.83 employees per reported executive.
Geoffrey Rotstein  CEO
President CEO, Director
Daniel Bradbury  Chairman
Chairman of the Board, CEO

Equillium's Insider Buying Vs Selling



Latest Trades

2022-08-29Jason A KeyesDisposed 7000 @ 2.83View
2022-06-06Jason A KeyesDisposed 5000 @ 2.52View
2022-04-04Jason A KeyesDisposed 8000 @ 3.18View
2021-12-01Jason A KeyesDisposed 5000 @ 5.08View
2021-10-06Stephen ConnellyDisposed 8092 @ 7.01View
2021-09-27Jason A KeyesDisposed 8000 @ 6.74View
2021-07-27Jason A. KeyesDisposed 5000 @ 5.72View
2021-06-08Stephen ConnellyDisposed 10495 @ 7.18View
2021-06-04Stephen ConnellyDisposed 13539 @ 7.01View
2021-05-26Jason A KeyesDisposed 5000 @ 6.5View
Monitoring Equillium's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Equillium. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.
To learn how to invest in Equillium Stock, please use our How to Invest in Equillium guide.

Equillium Management Team Effectiveness

The company has Return on Asset (ROA) of (0.1408) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1408. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.4892) %, which implies that it produced no returns to current stockholders. Equillium's management efficiency ratios could be used to measure how well Equillium manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/23/2024, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to drop to -0.66. At this time, Equillium's Total Current Liabilities is relatively stable compared to the past year. As of 04/23/2024, Liabilities And Stockholders Equity is likely to grow to about 67.5 M, while Non Current Liabilities Total is likely to drop slightly above 364.8 K.
As of 04/23/2024, Common Stock Shares Outstanding is likely to drop to about 25.8 M. In addition to that, Net Loss is likely to grow to about (53.4 M)

Equillium Workforce Comparison

Equillium is rated below average in number of employees category among related companies. The total workforce of Health Care industry is currently estimated at about 1,616. Equillium holds roughly 44.0 in number of employees claiming about 2.72% of equities under Health Care industry.

Equillium Profit Margins

The company has Net Profit Margin (PM) of (0.37) %, which may indicate that it does not properly execute on its own pricing strategies. This is way below average. Likewise, it shows Net Operating Margin (NOM) of (0.35) %, which signifies that for every 100 dollars of sales, it has a net operating loss of $0.35.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.790.9965
Significantly Down
Slightly volatile

Equillium Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Equillium insiders, such as employees or executives, is commonly permitted as long as it does not rely on Equillium's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Equillium insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Equillium Notable Stakeholders

An Equillium stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Equillium often face trade-offs trying to please all of them. Equillium's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Equillium's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Geoffrey RotsteinPresident CEO, DirectorProfile
Daniel BradburyChairman of the Board, CEOProfile
Vernon LoboIndependent Chairman of the BoardProfile
Bruce SteelPresident Chief Business Officer and DirectorProfile
Bruce CFAPresident, CoFounderProfile
Peter KanniahCFO, SecretaryProfile
PMP MBASenior COOProfile
Dilshan KathriarachchiCTOProfile
John FisherIndependent DirectorProfile
Anthony TjanIndependent DirectorProfile
Marc LavineIndependent DirectorProfile
Charles McDermottIndependent DirectorProfile
Bala ManianIndependent DirectorProfile
Stephen ConnellyChief Scientific Officer, DirectorProfile
Martha DemskiIndependent DirectorProfile
Mark PruzanskiIndependent DirectorProfile
Jason KeyesChief OfficerProfile
Penny TomPrincipal OfficerProfile
Joel RothmanChief OfficerProfile
Krishna PoluChief Medical OfficerProfile
Matthew RitterSenior DevelopmentProfile
Maple MDChief OfficerProfile
Krishna MDConsultantProfile
Michael MooreVice CommunicationsProfile

About Equillium Management Performance

The success or failure of an entity such as Equillium often depends on how effective the management is. Equillium management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Equillium management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Equillium management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.26)(0.28)
Return On Capital Employed(0.63)(0.66)
Return On Assets(0.26)(0.28)
Return On Equity(0.59)(0.62)
The data published in Equillium's official financial statements usually reflect Equillium's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Equillium. For example, before you start analyzing numbers published by Equillium accountants, it's critical to develop an understanding of what Equillium's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Equillium's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Equillium's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Equillium's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Equillium. Please utilize our Beneish M Score to check the likelihood of Equillium's management manipulating its earnings.

Equillium Workforce Analysis

Traditionally, organizations such as Equillium use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Equillium within its industry.

Equillium Manpower Efficiency

Return on Equillium Manpower

Revenue Per Employee820.1K
Revenue Per Executive1.5M
Net Loss Per Employee303.1K
Net Loss Per Executive555.6K
Working Capital Per Employee494.9K
Working Capital Per Executive907.3K
When determining whether Equillium is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Equillium Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Equillium Stock. Highlighted below are key reports to facilitate an investment decision about Equillium Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Equillium. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index.
To learn how to invest in Equillium Stock, please use our How to Invest in Equillium guide.
You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Complementary Tools for Equillium Stock analysis

When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
CEOs Directory
Screen CEOs from public companies around the world
Is Equillium's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Equillium. If investors know Equillium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Equillium listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
Revenue Per Share
Quarterly Revenue Growth
Return On Assets
Return On Equity
The market value of Equillium is measured differently than its book value, which is the value of Equillium that is recorded on the company's balance sheet. Investors also form their own opinion of Equillium's value that differs from its market value or its book value, called intrinsic value, which is Equillium's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Equillium's market value can be influenced by many factors that don't directly affect Equillium's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Equillium's value and its price as these two are different measures arrived at by different means. Investors typically determine if Equillium is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Equillium's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.